CN115282149A - 用抗癌剂治疗血液恶性肿瘤 - Google Patents

用抗癌剂治疗血液恶性肿瘤 Download PDF

Info

Publication number
CN115282149A
CN115282149A CN202211003162.1A CN202211003162A CN115282149A CN 115282149 A CN115282149 A CN 115282149A CN 202211003162 A CN202211003162 A CN 202211003162A CN 115282149 A CN115282149 A CN 115282149A
Authority
CN
China
Prior art keywords
compound
administered
day
subject
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211003162.1A
Other languages
English (en)
Chinese (zh)
Inventor
索拉雅·卡兰西奥
保罗·霍伦巴赫
安东尼娅·洛佩兹-吉罗纳
凯尔·麦克白
迈克尔·普尔德纳德
艾里特·拉普莱
陆刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CN115282149A publication Critical patent/CN115282149A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202211003162.1A 2016-06-06 2017-06-05 用抗癌剂治疗血液恶性肿瘤 Pending CN115282149A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662346344P 2016-06-06 2016-06-06
US62/346,344 2016-06-06
CN201780035323.6A CN109414436A (zh) 2016-06-06 2017-06-05 用2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺治疗血液恶性肿瘤
PCT/US2017/035892 WO2017214014A1 (en) 2016-06-06 2017-06-05 Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780035323.6A Division CN109414436A (zh) 2016-06-06 2017-06-05 用2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺治疗血液恶性肿瘤

Publications (1)

Publication Number Publication Date
CN115282149A true CN115282149A (zh) 2022-11-04

Family

ID=60482040

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211003162.1A Pending CN115282149A (zh) 2016-06-06 2017-06-05 用抗癌剂治疗血液恶性肿瘤
CN201780035323.6A Pending CN109414436A (zh) 2016-06-06 2017-06-05 用2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺治疗血液恶性肿瘤

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780035323.6A Pending CN109414436A (zh) 2016-06-06 2017-06-05 用2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺治疗血液恶性肿瘤

Country Status (15)

Country Link
US (4) US10245258B2 (OSRAM)
EP (1) EP3463358A4 (OSRAM)
JP (1) JP7163281B2 (OSRAM)
KR (1) KR20190015300A (OSRAM)
CN (2) CN115282149A (OSRAM)
AU (2) AU2017278114B2 (OSRAM)
BR (1) BR112018075206A2 (OSRAM)
CA (1) CA3026396A1 (OSRAM)
CL (1) CL2018003499A1 (OSRAM)
EA (1) EA201892746A1 (OSRAM)
IL (1) IL262565B (OSRAM)
MX (1) MX388717B (OSRAM)
SG (1) SG11201809501PA (OSRAM)
WO (1) WO2017214014A1 (OSRAM)
ZA (1) ZA201807105B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
CA3010801A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
US11535603B1 (en) 2016-09-30 2022-12-27 Deuterx, Llc Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same
RS64976B1 (sr) 2016-12-01 2024-01-31 Arvinas Operations Inc Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora
MX2021007800A (es) * 2018-12-31 2021-10-26 Celgene Corp Composiciones y metodos para usar 2-(4-clorofenil)-n-((2-(2,6-diox opiperidin-3-il)-1-ox-oisoindolin-5il)metil)-2,2-difluoroacetamid a.
CN114667147B (zh) 2019-08-26 2024-09-06 阿尔维纳斯运营股份有限公司 用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
MX2022004729A (es) 2019-10-21 2022-05-13 Celgene Corp Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y segundos principios activos para uso combinado.
CA3157196A1 (en) * 2019-11-05 2021-05-14 Celgene Corporation Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide
IL293481A (en) 2019-12-06 2022-08-01 Celgene Corp Processes for preparing 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
AU2021239822A1 (en) * 2020-03-16 2022-10-13 Celgene Corporation Combination therapy for acute myeloid leukemia
CR20230162A (es) * 2020-09-14 2023-06-02 Arvinas Operations Inc Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos
EP4217352A4 (en) 2020-09-23 2024-04-10 St. Jude Children's Research Hospital, Inc. Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
KR20240066906A (ko) * 2022-11-08 2024-05-16 주식회사 온코드바이오 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0501186A2 (en) * 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20090175869A1 (en) * 2007-05-31 2009-07-09 Ascenta Therapeutics, Inc. Pulsatile Dosing of Gossypol for Treatment of Disease
SI2263677T1 (sl) 2009-05-20 2011-07-29 Hybrigenics Sa Nove terapevtske uporabe inecalcitola
EP2773322A1 (en) * 2011-11-01 2014-09-10 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
ES2785203T3 (es) * 2013-12-05 2020-10-06 Hoffmann La Roche Tratamiento de combinación novedoso para leucemia mielógena aguda (LMA)
US9499514B2 (en) * 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
BR112018013761A2 (pt) 2016-01-08 2018-12-11 Celgene Corp compostos antiproliferativos e suas composições farmacêuticas e usos
CN108712904B (zh) 2016-01-08 2022-08-02 细胞基因公司 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的固体形式以及其药物组合物和用途
CN108601777B (zh) * 2016-01-08 2021-08-03 细胞基因公司 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的制剂

Also Published As

Publication number Publication date
US10245258B2 (en) 2019-04-02
KR20190015300A (ko) 2019-02-13
US20210154182A1 (en) 2021-05-27
US20170348298A1 (en) 2017-12-07
IL262565A (en) 2018-12-31
EA201892746A1 (ru) 2019-06-28
BR112018075206A2 (pt) 2019-03-19
MX388717B (es) 2025-03-20
SG11201809501PA (en) 2018-12-28
EP3463358A4 (en) 2020-07-22
AU2017278114A1 (en) 2018-11-29
JP2019517587A (ja) 2019-06-24
CL2018003499A1 (es) 2019-03-15
US11590117B2 (en) 2023-02-28
MX2018015120A (es) 2019-04-15
AU2023202159A1 (en) 2023-05-04
ZA201807105B (en) 2020-01-29
IL262565B (en) 2022-08-01
AU2017278114B2 (en) 2023-01-12
US20190175573A1 (en) 2019-06-13
JP7163281B2 (ja) 2022-10-31
EP3463358A1 (en) 2019-04-10
CN109414436A (zh) 2019-03-01
CA3026396A1 (en) 2017-12-14
WO2017214014A1 (en) 2017-12-14
US20230158009A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
US20230158009A1 (en) Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6- dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
EP3644999B1 (en) Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
US10626101B2 (en) Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
EP3808346B1 (en) Antiproliferative compounds for use in the treatment of leukemia
US20220389515A1 (en) Use of biomarkers to predict clinical sensitivity to 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
CN111542321A (zh) 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的同位素体
US20230149379A1 (en) Combination therapy for acute myeloid leukemia
US20220378773A1 (en) Methods for treating leukemia and use of a leukemic stem cell signature to predict clinical sensitivity to therapies
US20210128545A1 (en) Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
NZ747409A (en) Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
HK40093203A (en) Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
HK40051637B (en) Antiproliferative compounds for use in the treatment of leukemia
HK40030243A (en) Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
HK40030243B (en) Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
HK40005153A (en) Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
HK40005153B (en) Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination